. During postnatal development, GDNF mRNA is undetectable in To test whether glial cell line-derived neurotrophic the mesencephalon, but is transiently expressed in the factor (GDNF) regulates the development of nigral dostriatum, the innervation target of nigral dopaminergic paminergic neurons in vivo, neonatal rats received bineurons (Schaar et al., 1993; Stroemberg et al., 1993 ; lateral injections of GDNF into the striatum. Injections Poulsen et al., 1994) . In adult rat brain, GDNF mRNA is at postnatal day 2 induced a unique transient behavundetectable, but its expression can be induced by limioral pattern characterized by forelimb hyperflexure, bic motor status epilepticus in striatum, hippocampus, clawed toes of all limbs, and a kinked tail. Parallel to and cortex (Schmidt-Kastner et al., 1994; Ho et al., 1995) . the behavioral changes, the levels of striatal and ven-A recent report demonstrated retrograde transport of tral mesencephalic dopamine and serotonin were iniodinated GDNF to nigral dopaminergic neurons followcreased from 60% to 100% with a proportional ining injection into the striatum of adult rats (Tomac et al., crease of principal metabolite levels. GDNF increased 1995b). tyrosine hydroxylase activity in the ventral mesen-
Introduction
Results Dopaminergic neurons in the ventral mesencephalon play a crucial role in the regulation of motor function, Single bilateral injections of 10 g of GDNF (5 g each and there is evidence for their involvement in cognitive side) into the striatum of postnatal day 2 (P2) rats proprocesses. The degeneration of dopaminergic neurons duced a striking and unique pattern of behavioral represents the defining feature of Parkinson's disease. changes ( Figure 1 ). Most prominent was the smaller size The development of this neuronal population has been of GDNF injected rats and the appearance of hyperdescribed in detail in the rat. Initial innervation of the flexed forelimbs that was maintained during all behavprincipal target areas (striatum, nucleus accumbens, olioral activities (Figures 1A, 1E, and 1F) . When lifted up, factory tubercle, and cortex) occurs prenatally. The pro-GDNF injected pups did not extend their forelimbs tojection matures during the first 2 weeks postnatally and ward a surface as normal animals do ( Figure 1B ). A exhibits a gradual increase in terminal density in the second obvious GDNF-induced behavioral difference target areas toward adult levels (Specht et al., 1981a, related to the appearance of the tails of the rats. Tails 1981b; Voorn et al., 1988; Broaddus and Bennett, 1990;  of pups injected with a control protein showed a smooth Arbogast and Voogt, 1991) .
curvature of the tail as did uninjected rats (Figures 1A A number of growth factors have been found to inand 1C). In contrast, GDNF injected rats showed multiple crease survival or differentiation (or both) of cultured kinks in their tails, reflecting increased muscle tension embryonic dopaminergic neurons Poulsen (Figures 1A and 1D) . Third, GDNF injected animals kept et Krieglstein and Unsicker, 1994) ; however, their toes in a clawed position (Figures 1A, 1D, and 1F) . glial cell line-derived neurotrophic factor (GDNF) has This phenomenon was observed both at forelimbs and been the only factor significantly protecting dopaminerhindlimbs. There was no obvious difference in locomotor gic neurons from lesion-induced degeneration in vivo activity between GDNF injected and control rats; however, control rats were more successful in gaining access to suckle. There were no obvious behavioral differ- † Present address: Idun Pharmaceuticals, 11085 Torrey Pines Road, Suite 300, La Jolla, California 92037.
ences between animals receiving control protein (P2) was given unilateral striatal injections of 5 g GDNF. Different from rats with bilateral injections, these unilaterally injected rats developed hyperflexure limited to the forelimb and, to a lesser degree, also the hindlimb contralateral to the injected side without an effect on the ipsilateral side ( Figure 1G ). In contrast with neonatal rats, adult rats receiving single GDNF injections (10 g) into the striatum or above the substantia nigra were unaffected in posture and behavior. Also the levels of dopamine, serotonin, and their respective metabolites were unaffected (Table 1) . GDNF-treated neonatal rats showed a slower rate of weight increase compared with cytochrome C injected and uninjected controls. There were significant differences in weight between GDNF-treated and control groups at 6 and 12 days (P8 and P14) after the intrastriatal injections (Figure 2 ). In parallel to the behavioral changes, the weight differences were no longer evident 26 days after the injections (P28).
To test for the hypothesis that the behavioral changes reflect alterations in the function of nigrostriatal neurons, we measured several biochemical and morphological dopaminergic parameters. Levels of striatal and ventral mesencephalic dopamine (DA) at P8 were increased by 60% and 100%, respectively, in GDNF-treated animals as compared with cytochrome C injected controls (Table  1) . At P14, the increases were reduced to 25% and 37%, respectively, and at P28, no significant difference could be detected. Levels of the principal DA metabolites, DOPAC and HVA, were increased proportionally to those of dopamine itself. Striatal and ventral mesencephalic levels of serotonin (5-HT) and its metabolite hydroxyindolaceticacid (HIAA) were increased by GDNF in parallel to the increases seen in DA and its metabolites (Table  1) . Compared with cytochrome C injected rats, at P8 were increased by 85% and 95%, respectively. At P14 Shown are rat pups at P8 that had received bilateral intrastriatal in GDNF injected rats, striatal 5-HT levels were not siginjections of GDNF at P2. (A) Comparison to a cytochrome C injected littermate (bottom). Note nificantly different from those in cytochrome C injected reduced body size and hyperflexed forelimbs in GDNF injected pup.
controls, but there was a 28% increase in the mesen-(B) When lifted up, GDNF injected pups do not extend their forelimbs.
cephalon. At P28, no significant differences could be (C-G) Tails of cytochrome C injected pups are smoothly curved (C), detected. Bilateral GDNF injection into the midbrain while GDNF injected rats show multiple kinks and toes are kept in above the substantia nigra produced increases of DA, a clawed position (D). Close up of forelimbs show normal positioning 5-HT, and metabolites in P8 striatum and ventral mesen-(E) and hyperflexion after GDNF injection (F); forelimbs were kept in this position during all activities. Unilateral striatal GDNF injections cephalon similar to those seen after striatal administrainduce contralateral forelimb hyperflexion (G). tion (Table 1) . Figure 3 shows the results of a dose-response analysis of the GDNF effect on tissue DA ( Figure 3A ) and 5-injections and uninjected controls. The behavioral HT levels ( Figure 3B ) at P8. Striatal injection of 0.05 g changes became evident 3-4 days after the injections of GDNF did not affect DA levels, while 0.5 g increased (P5-P6) and were most evident in the period between DA by 25% and 29% above levels measured in striatum 6-12 days after the injections (P8-P14). They gradually and ventral mesencephalon, respectively, of animals indeclined in intensity thereafter and were no longer presjected with control protein. Following 5 g of GDNF, ent 26 days after the GDNF injections (P28). Rats instriatal DA was increased by 57% and mesencephalic jected with 5 g of GDNF could not be behaviorally dopamine by 95%. DOPAC and HVA levels were indistinguished from rats injected with 10 g. While adcreased proportionally (data not shown). 5-HT levels ministration of 0.05 g of GDNF did not produce behavwere increased by GDNF in a similar fashion ( Figure 3B ): ioral changes, rats injected with 0.5 g displayed slight 0.05 g of GDNF produced no significant changes, 0.5 paw clawing and tail kinking, but no forelimb hyperflexg increased striatal and mesencephalic 5-HT by 37% ion (data not shown). Bilateral injection of a total of and 45%, respectively, while 5 g of GDNF produced a 10 g of GDNF above the substantia nigra of P2 rats maximal increase of 55% and 88%, respectively. HIAA produced identical transient behavioral changes (data levels were increased proportionally (data not shown).
To test whether the increased DA levels reflect the not shown). In addition, one group of neonatal animals DA (A) and 5-HT (B) levels in P8 rats after bilateral striatal injection of GDNF. Equal volumes of GDNF dilutions were injected at P2, and DA/5-HT levels were determined in P8 striata and ventral mesencephali as described in Experimental Procedures. Asterisks indi- Figure 2 . Postnatal Increase in Body and Brain Weights cate statistically significant differences from corresponding control Data for body (A) or brain (B) weights from control rats (closed and cytochrome C groups (one asterisk, p < 0.05; two asterisks, bars) and from rats following injection of GDNF (dotted bars) or p < 0.01; Student's t test). P8 rats injected with 0.05 g GDNF cytochrome C (hatched bars). Asterisks indicate statistically signifidid not show any behavioral changes, those injected with 0.5 g cant differences from corresponding control and cytochrome C displayed slight paw clawing and tail kinking, but no forelimb hypergroups (one asterisk, p < 0.05; two asterisks, p < 0.01; Student's t flexion. The group injected with 5 g GDNF showed the full dystoniatest).
like pattern seen after 10 g GDNF.
[
3 H]Mazindol-binding site density served as an addiinduction of synthesizing enzyme in dopaminergic neutional parameter to test for changes in dopaminergic rites, we measured tyrosine hydroxylase activity in striaterminal density (Javitch et al., 1984) . This parameter tum and ventral mesencephalon of GDNF injected was moderately increased by GDNF at P8 (40% , Table  animals and visualized this enzyme with immunohisto-5), but was back to control levels by P14, when the chemical methods. An increase in tyrosine hydroxylase behavioral changes still were maximal. The absence of (TH) activity (48%) was found in the mesencephalon but strong changes of mazindol-binding site density and not striatum ( Table 2 ). The activity of choline acetyltransdensity of TH-positive fibers in the striatum does not ferase (ChAT, a marker enzyme for striatal cholinergic support the view that the more robust increases in dopainterneurons) in striatal tissue and ␥-aminobutyric acid mine levels reflect sprouting of nigrostriatal terminals. (GABA) uptake into striatal synaptosomes were not affected by GDNF administration (Table 3) .
No differences between GDNF-treated and control sity, failing to support the hypothesis that GDNF stimuTissue Control (9) Cytochrome C (7) GDNF (7) lates sprouting of dopaminergic neurites (Figure 4 ). Ab- TH-positive neurons were not affected by GDNF treata Statistically significant difference compared with corresponding ment (Table 4) .
cytochrome C injected group (p Ͻ 0.001; Student's t test). Also the the distribution and density of 5-HT immunopattern is reminiscent of the clinical condition dystonia, which is characterized by muscular hypertonus and ristaining in the striataum and ventral mesencephalon was unaffected by GDNF (data not shown).
gidity (Adams and Victor 1993) . Dystonia is a CNS dysfunction rather than a disorder of muscles. There are hereditary and idiopathic forms of dystonia, and the Discussion disorder can be generalized or limited to specific muscle groups. The etiologies of the different clinical forms of The unique behavioral pattern induced by GDNF injections into the striatum of neonatal rats represents the dystonia are largely unclear, but a possible involvement of dopaminergic mechanisms has been proposed based most significant finding of the present study. GDNF induced transient hyperflexure of forelimbs and the apon the fact that patients suffering from generalized dystonias usually get some symptomatic relief from pearance of clawed toes and kinked tails. The behavioral alterations were associated with increases in DA levels treatment with centrally acting dopamine antagonists, muscarinic agonists, or in more progressed cases, with but not markers of dopaminergic fiber density, suggesting that they were caused by increased DA metabo-L-DOPA (Adams and Victor, 1993) . Our biochemical analysis showed effects of GDNF lism rather than sprouting of dopaminergic terminals. The transient increase in DA levels was accompanied by on dopaminergic and, in addition, also on serotonergic neurons. Both transmitter systems are interacting extena parallel elevation of 5-HT tissue levels, but no altered distribution of 5-HT immunostaining.
sively as suggested by the reciprocal anatomical projections between dopaminergic neurons in substantia niThe combination of behavioral changes induced by intrastriatal GDNF has not been described before. The gra/VTA and serotonergic neurons in the dorsal raphe we cannot completely exclude a potential direct action and no change in DA or 5-HT synthesis or turnover.
Values are means Ϯ SEM of cell counts from both sides with each
These results are in contrast with data reported by Hudsixth section used for analysis and multiplication of the result by son et al. (1995) . For our studies, we used adult (240-250 six. Average cell sizes were determined from ten randomly selected nigral TH-positive neurons per rat and per three corresponding levg) Fisher 344 and Wistar rats (data not shown), and for els (30 cells per rat in total). Number of rats per group is indicated the supranigral injections, we followed the coordinates in parentheses.
and injection protocol described by Hudson et al. (1995) . In addition to the lack of sprouting of TH-positive fibers in this study, we had reported earlier that repeated nigral GDNF injections did not affect the numbers of mesencenucleus (DRN; Dray et al., 1976; Pasquier et al, 1977; Azmitia and Segal, 1978; Herve et al., 1987; Kalen et al., phalic TH-immunopositive neurons and did not induce dopaminergic neuron sprouting in normal unlesioned 1988; Nedergaard et al., 1988; Van Bockstaele et al., 1993) . Pharmacological interactions between both animals (Beck et al., 1995) . However, Hudson et al. (1995) did not provide any information about the actual weight transmitter systems have been studied extensively using DA and 5-HT agonists and antagonists and intracranor age of their experimental animals. A grossly different weight of the rats used in their studies compared with ial microdialysis probes in freely moving rats, but the results were rather controversial (Benloucif and Galloour animals would be likely to result in slightly different actual injection sites using identical stereotaxic coordiway, 1991; Huang and Nichols, 1993; Ferre et al., 1994; Yadid et al., 1994; Dewey et al., 1995) . Iontophoretic nates. In addition, if the rats used by Hudson et al. (1995) were significantly younger, mesencephalic dopamineradministration of 5-HT to the SN reduced electrical activity of nigral dopaminergic neurons, and electrical stimugic neurons could still be partially responsive to GDNF, or if they were much older, it might be possible that they lation of the DRN has been reported to both activate and inhibit SN neurons (Dray et al., 1978) . Recently, had regained responsiveness. Recently, Tomac et al. (1995b) reported retrograde transport of iodinated using positron emission tomography in baboons, Dewey et al. (1995) reported data consistent with an inhibitory GDNF from striatum to nigral dopaminergic cell bodies as well as GDNF immunoreactivity in dopaminergic neuaction of 5-HT on striatal DA release. However, the net effect of 5-HT on dopaminergic neuron activity and DA rons in adult rats. Although these results suggest a role for GDNF in adult rats, they do not provide direct evirelease might be dependent on the functional status of dopaminergic neurons. In turn, there is also evidence dence. Our behavioral findings in early postnatal rats are very for modulatory actions of DA on serotonergic neurons in the DRN: increased DA levels in the DRN inhibit the different from those produced by drugs inducing acute dopaminergic hyperfunction. Compounds such as amactivity of serotonergic neurons projecting to the striatum via local 5-HT release and autoreceptor stimulation phetamine or cocaine, which induce the release of DA and 5-HT, produce a general locomotor hyperactivity of within the DRN. However, striatal and systemic administration of dopaminergic agonists does not affect striatal animals. Similar locomotor activation is observed after the injections of the DA precursor L-DOPA and of direct 5-HT release (Ferre et al., 1994) . These data, together with the important finding that GDNF does not affect DA receptor agonists such as apomorphine (Greenberg et al., 1974; Beninger, 1983; Bergman et al., 1989) . All serotonergic neurons cocultured with dopaminergic neurons (Lin et al., 1993; Poulsen et al, 1994) , suggest these drugs result in the continuous stimulation of DA and 5-HT receptors, overriding the naturally occurring that the primary action of GDNF in our study is on developing dopaminergic neurons. The concommittant intransmitter release. GDNF injections resulted in robust elevations of DA and 5-HT levels and of their metabolites crease of 5-HT levels is most likely secondary and reflects an adaptive upregulation of serotonergic in striatum and substantia nigra, in absence of evidence for morphological changes of nigrostriatal dopaminergic transmitter synthesis inhibiting dopaminergic neuron activity and DA release. However, based on our analysis, fibers and of serotonergic projections. The increase in Rat recombinant GDNF was produced, purified, and tested for biospecific genes of the transmitter machinery of dopaminlogical activity as described previously (Beck et al., 1995) . Neonatal ergic and, as a secondary event, also of serotonergic rats (P2, Wistar) were cold anesthesized and put on a custom-made neurons. The fact that GDNF administration elevated TH stage (modeling clay) that fixed the rats in a prone position. The activity supports this view. Thus, it seems likely that stage was positioned in a stereotaxic frame. For injections, the skin over the skull was disinfected by wiping twice with 70% ethanol.
GDNF injections as performed in the present study in- I. An examination of D1 and D2 The P2 synaptosome fraction of dissected and homogenized striatal tissue was prepared as described by Lapchak et al. (1993) . Specific receptors, adenylate cyclase regulation and presynaptic dopamine markers. Dev. Brain Res. 52, 265-271. GABA uptake was determined using the protocol by Casper et al. (1991) , as the fraction of uptake sensitive to 10 M of the selective Buj-Bello, A., Buchman, V.L., Horton, A., Rosenthal, A., and Davies, inhibitor NO-711 (95% of total uptake).
A .M. (1995) . GDNF is an age-specific survival factor for sensory and autonomic neurons. (1978) . and collected into PBS containing 0.02% NaN 3. Every tenth section
The dorsal and medial raphe projections to the substantia nigra in spanning the striatum and every sixth section spanning the substanthe rat: electrophysiological, biochemical and behavioral observatia nigra were stained for TH as described previously (Beck et al., tions. Brain Res. 151, 431-442. 1995) . To minimize section to section variations, during all steps of the immunohistochemistry, sections from one control, cytochrome Ebendal, T., Tomac, A., Hoffer, B.J., and Olson, L. (1995) . Glial cell C and GDNF injected rat were processed simultaneously, using line-derived neurotrophic factor stimulates fiber formation and surstaining racks that permitted incubation of all sections in the same vival in cultured neurons from peripheral autonomic ganglia J. Neusolutions. Only sections that were stained together were used for rosci. Res. 40, 276-284. histological comparisons.
Ferre, S., Cortes, R., and Artigas, F. (1994) . Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in
